Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
Merus B.V.
Pfizer
Syndax Pharmaceuticals
Incyte Corporation
DEKA Biosciences
Persephone Biosciences
Celldex Therapeutics
Amgen
Sinocelltech Ltd.
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Boston Scientific Corporation
Shenzhen Hornetcorn Bio-technology Company, LTD
Hoffmann-La Roche
Light Sciences LLC
Light Sciences LLC
FeRx